When was Kanvas Biosciences founded?

Kanvas Biosciences was founded in 2021 and raised its 1st funding round 2 years after it was founded.

Where is Kanvas Biosciences located?

Kanvas Biosciences is headquartered in Ithaca, United States.

How many employees does Kanvas Biosciences have?

As of Jun 30, 2026, the latest employee count at Kanvas Biosciences is 42.

Is Kanvas Biosciences a funded company?

Kanvas Biosciences is a funded company, having raised a total of $77.5M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jun 13, 2023.

When was the latest funding round of Kanvas Biosciences?

Kanvas Biosciences' latest funding was a $***** Series A round on May 07, 2026, with participation from 8 investors. Its primary sector is Gastroenterology. In United States, the Gastroenterology sector has seen $596M in funding in 2026 to date.

Where does Kanvas Biosciences rank among its competitors?

Kanvas Biosciences ranks 90th amongst 3348 active competitors, of which 1135 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Kanvas Biosciences?

Kanvas Biosciences' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Kanvas Biosciences - 2026 Company Profile, Team, Funding & Competitors

Company Details

Website: www.kanvasbio.com/
Email ID: *****@kanvasbio.com

Key Metrics

Founded Year

2021

Location

Ithaca, United States

Stage

Series A

Total Funding

$77.5M in 3 rounds

Latest Funding Round

Series A, May 07, 2026, $*****

Investors

DCVC & 12 more

Ranked

90^th among 3348 active competitors

Employee Count

42 as on Jun 30, 2026

Similar Companies

Jazz Pharmaceuticals & 3030 more

View Kanvas Biosciences' full profile

Kanvas Biosciences has raised a total funding of $77.5M over 3 rounds. Its first funding round was on Jun 13, 2023. Its latest funding round was a Series A round on May 07, 2026 for $*****. 8 investors participated in its latest round. Kanvas Biosciences has 13 institutional investors.

Here is the list of recent funding rounds of Kanvas Biosciences:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 07, 2026	6823060	Series A	9336116	1255218	4910473	1727144
Mar 04, 2024	6846527	Series A	3587092	3512026	8624184	Lion Capital & 4 more
Jun 13, 2023	3863047	Seed	8452204	2503017	DCVC	Lion Capital & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Kanvas Biosciences's funding rounds and investors

The founders of Kanvas Biosciences are Iwijn De Vlaminck and Matthew P Cheng.

Here are the details of Kanvas Biosciences' key team members:

Iwijn De Vlaminck: Co-Founder of Kanvas Biosciences.
Contact Info: 1 email address
Matthew P Cheng: Co-Founder of Kanvas Biosciences.

View details of Kanvas Biosciences's Founder profiles and Board Members

Kanvas Biosciences' employee count trend

Kanvas Biosciences has 42 employees as of Jun 26. Here is Kanvas Biosciences's employee count trend over the years:

Employee count trend for Kanvas Biosciences

Uncover Kanvas Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Kanvas Biosciences include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Kanvas Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 18 others	73/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
90th	Kanvas Biosciences 2021, Ithaca (United States), Series A	Provider of imaging solutions for microbial research and infectious diseases	$77.5M	Uncommon Denominator, Gates & 11 others	63/100